This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Eisbruch, A. Articles by Lawrence, T. S. Search for Related Content PubMed PubMed Citation Articles by Eisbruch, A. Articles by Lawrence, T. S. Social Bookmarking                            What's this?

Radiation Concurrent With Gemcitabine for Locally Advanced Head and Neck Cancer: A Phase I Trial and Intracellular Drug Incorporation Study

From the Departments of Radiation Oncology, Pharmacology, Otolaryngology–Head and Neck Surgery; and Medicine, University of Michigan Medical Center, and Ann Arbor Veterans Affairs Hospital, Ann Arbor, MI.

Address reprint requests to Avraham Eisbruch, MD, Department of Radiation Oncology, University of Michigan Hospital, Ann Arbor, MI 48109; email: eisbruch{at}umich.edu

PURPOSE: To examine the feasibility and dose-limiting toxicity (DLT) of once-weekly gemcitabine at doses predicted in preclinical studies to produce radiosensitization, concurrent with a standard course of radiation for locally advanced head and neck cancer. Tumor incorporation of gemcitabine triphosphate (dFdCTP) was measured to assess whether adequate concentrations were achieved at each dose level.

PATIENTS AND METHODS: Twenty-nine patients with unresectable head and neck cancer received a course of radiation (70 Gy over 7 weeks, 5 days weekly) concurrent with weekly infusions of low-dose gemcitabine. Tumor biopsies were performed after the first gemcitabine infusion (before radiation started), and the intracellular concentrations of dFdCTP were measured.

RESULTS: Severe acute and late mucosal and pharyngeal-related DLT required de-escalation of gemcitabine dose in successive patient cohorts receiving dose levels of 300 mg/m²/wk, 150 mg/m²/wk, and 50 mg/m²/wk. No DLT was observed at 10 mg/m²/wk. The rate of endoscopy- and biopsy-assessed complete tumor response was 66% to 87% in the various cohorts. Tumor dFdCTP levels were similar in patients receiving 50 to 300 mg/m² (on average, 1.55 pmol/mg, SD 1.15) but were barely or not detectable at 10 mg/m².

CONCLUSION: A high rate of acute and late mucosa-related DLT and a high rate of complete tumor response were observed in this regimen at the dose levels of 50 to 300 mg/m², which also resulted in similar, subcytotoxic intracellular dFdCTP concentrations. These results demonstrate significant tumor and normal tissue radiosensitization by low-dose gemcitabine. Different regimens of combined radiation and gemcitabine should be evaluated, based on newer preclinical data promising an improved therapeutic ratio.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. Shibata, A. Raubitschek, L. Leong, M. Koczywas, L. Williams, J. Zhan, and J. Y.C. Wong A Phase I Study of a Combination of Yttrium-90-Labeled Anti-Carcinoembryonic Antigen (CEA) Antibody and Gemcitabine in Patients with CEA-Producing Advanced Malignancies Clin. Cancer Res., April 15, 2009; 15(8): 2935 - 2941. [Abstract] [Full Text] [PDF]

				J. L. Marti, H. S. Hochster, S. P. Hiotis, B. Donahue, T. Ryan, and E. Newman Phase I/II Trial of Induction Chemotherapy Followed by Concurrent Chemoradiotherapy and Surgery for Locoregionally Advanced Pancreatic Cancer Ann. Surg. Oncol., December 1, 2008; 15(12): 3521 - 3531. [Abstract] [Full Text] [PDF]

				L.-S. Tham, L. Wang, R. A. Soo, S.-C. Lee, H.-S. Lee, W.-P. Yong, B.-C. Goh, and N. H.G. Holford A Pharmacodynamic Model for the Time Course of Tumor Shrinkage by Gemcitabine + Carboplatin in Non-Small Cell Lung Cancer Patients Clin. Cancer Res., July 1, 2008; 14(13): 4213 - 4218. [Abstract] [Full Text] [PDF]

				S. A. Veltkamp, J. H. Beijnen, and J. H.M. Schellens Prolonged Versus Standard Gemcitabine Infusion: Translation of Molecular Pharmacology to New Treatment Strategy Oncologist, March 1, 2008; 13(3): 261 - 276. [Abstract] [Full Text] [PDF]

				V. Gandhi Questions About Gemcitabine Dose Rate: Answered or Unanswered? J. Clin. Oncol., December 20, 2007; 25(36): 5691 - 5694. [Full Text] [PDF]

				P. M. Specenier, D. Van den Weyngaert, C. Van Laer, J. Weyler, J. Van den Brande, M. T. Huizing, J. Dyck, D. Schrijvers, and J. B. Vermorken Phase II feasibility study of concurrent radiotherapy and gemcitabine in chemonaive patients with squamous cell carcinoma of the head and neck: long-term follow up data Ann. Onc., November 1, 2007; 18(11): 1856 - 1860. [Abstract] [Full Text] [PDF]

				D. S. Shewach and T. S. Lawrence Antimetabolite Radiosensitizers J. Clin. Oncol., September 10, 2007; 25(26): 4043 - 4050. [Abstract] [Full Text] [PDF]

				S. A. Flanagan, B. W. Robinson, C. M. Krokosky, and D. S. Shewach Mismatched nucleotides as the lesions responsible for radiosensitization with gemcitabine: a new paradigm for antimetabolite radiosensitizers Mol. Cancer Ther., June 1, 2007; 6(6): 1858 - 1868. [Abstract] [Full Text] [PDF]

				F. Y. Feng, C. A. Lopez, D. P. Normolle, S. Varambally, X. Li, P. Y. Chun, M. A. Davis, T. S. Lawrence, and M. K. Nyati Effect of Epidermal Growth Factor Receptor Inhibitor Class in the Treatment of Head and Neck Cancer with Concurrent Radiochemotherapy In vivo Clin. Cancer Res., April 15, 2007; 13(8): 2512 - 2518. [Abstract] [Full Text] [PDF]

				D. I. Rosenthal, J. S. Lewin, and A. Eisbruch Prevention and Treatment of Dysphagia and Aspiration After Chemoradiation for Head and Neck Cancer J. Clin. Oncol., June 10, 2006; 24(17): 2636 - 2643. [Abstract] [Full Text] [PDF]

				P. Y. Chun, F. Y. Feng, A. M. Scheurer, M. A. Davis, T. S. Lawrence, and M. K. Nyati Synergistic Effects of Gemcitabine and Gefitinib in the Treatment of Head and Neck Carcinoma Cancer Res., January 15, 2006; 66(2): 981 - 988. [Abstract] [Full Text] [PDF]

				P. M. Anderson, G. A. Wiseman, L. Erlandson, V. Rodriguez, B. Trotz, S. A. Dubansky, and K. Albritton Gemcitabine Radiosensitization after High-Dose Samarium for Osteoblastic Osteosarcoma Clin. Cancer Res., October 1, 2005; 11(19): 6895 - 6900. [Abstract] [Full Text] [PDF]

				M. A. Morgan, L. A. Parsels, J. D. Parsels, A. K. Mesiwala, J. Maybaum, and T. S. Lawrence Role of Checkpoint Kinase 1 in Preventing Premature Mitosis in Response to Gemcitabine Cancer Res., August 1, 2005; 65(15): 6835 - 6842. [Abstract] [Full Text] [PDF]

				B. Pauwels, A. E.C. Korst, F. Lardon, and J. B. Vermorken Combined Modality Therapy of Gemcitabine and Radiation Oncologist, January 1, 2005; 10(1): 34 - 51. [Abstract] [Full Text] [PDF]

				M. T. Milano, D. J. Haraf, K. M. Stenson, M. E. Witt, C. Eng, B. B. Mittal, A. Argiris, H. Pelzer, M. F. Kozloff, and E. E. Vokes Phase I Study of Concomitant Chemoradiotherapy with Paclitaxel, Fluorouracil, Gemcitabine, and Twice-Daily Radiation in Patients with Poor-Prognosis Cancer of the Head and Neck Clin. Cancer Res., August 1, 2004; 10(15): 4922 - 4932. [Abstract] [Full Text] [PDF]

				E. Kent, H. Sandler, J. Montie, C. Lee, J. Herman, P. Esper, J. Fardig, and D. C. Smith Combined-Modality Therapy With Gemcitabine and Radiotherapy As a Bladder Preservation Strategy: Results of a Phase I Trial J. Clin. Oncol., July 1, 2004; 22(13): 2540 - 2545. [Abstract] [Full Text] [PDF]

				M. Benasso, R. Corvo, A. Ponzanelli, G. Sanguineti, I. Ricci, E. Pallestrini, A. Santelli, V. Vitale, and R. Rosso Alternating gemcitabine and cisplatin with gemcitabine and radiation in stage IV squamous cell carcinoma of the head and neck Ann. Onc., April 1, 2004; 15(4): 646 - 652. [Abstract] [Full Text] [PDF]

				J. Aguilar-Ponce, M. Granados-Garcia, V. Villavicencio, A. Poitevin-Chacon, D. Green, A. Duenas-Gonzalez, A. Herrera-Gomez, K. Luna-Ortiz, A. Alvarado, H. Martinez-Said, et al. Phase II trial of gemcitabine concurrent with radiation for locally advanced squamous cell carcinoma of the head and neck Ann. Onc., February 1, 2004; 15(2): 301 - 306. [Abstract] [Full Text] [PDF]

				M. Machtay Phase I's, Photons, and Philosophies: New Tactics for Exploratory Clinical Trials of Concurrent Chemoradiation J. Clin. Oncol., January 15, 2004; 22(2): 214 - 216. [Full Text] [PDF]

				R. Gorlick, P. Anderson, I. Andrulis, C. Arndt, G. P. Beardsley, M. Bernstein, J. Bridge, N.-K. Cheung, J. S. Dome, D. Ebb, et al. Biology of Childhood Osteogenic Sarcoma and Potential Targets for Therapeutic Development: Meeting Summary Clin. Cancer Res., November 15, 2003; 9(15): 5442 - 5453. [Abstract] [Full Text] [PDF]

				B. W. Robinson, M. M. Im, M. Ljungman, F. Praz, and D. S. Shewach Enhanced Radiosensitization with Gemcitabine in Mismatch Repair-Deficient HCT116 Cells Cancer Res., October 15, 2003; 63(20): 6935 - 6941. [Abstract] [Full Text] [PDF]

				D. S. Shewach and T. S. Lawrence It's What's Inside That Counts J. Clin. Oncol., September 15, 2003; 21(18): 3383 - 3384. [Full Text] [PDF]

				P. D. Jones, L.-P. de Lorimier, B. E. Kitchell, and J. M. Losonsky Gemcitabine as a Radiosensitizer for Nonresectable Feline Oral Squamous Cell Carcinoma J. Am. Anim. Hosp. Assoc., September 1, 2003; 39(5): 463 - 467. [Abstract] [Full Text] [PDF]

				D. V. Gold, K. Schutsky, D. Modrak, and T. M. Cardillo Low-Dose Radioimmunotherapy (90Y-PAM4) Combined with Gemcitabine for the Treatment of Experimental Pancreatic Cancer Clin. Cancer Res., September 1, 2003; 9(10): 3929S - 3937. [Abstract] [Full Text] [PDF]

				J. W. G. van Putten, A. Price, A. H. D. van der Leest, A. Gregor, F. A. Little, and H. J. M. Groen A Phase I Study of Gemcitabine with Concurrent Radiotherapy in Stage III, Locally Advanced Non-Small Cell Lung Cancer Clin. Cancer Res., July 1, 2003; 9(7): 2472 - 2477. [Abstract] [Full Text] [PDF]

				B. W. Robinson and D. S. Shewach Radiosensitization by Gemcitabine in p53 Wild-Type and Mutant MCF-7 Breast Carcinoma Cell Lines Clin. Cancer Res., August 1, 2001; 7(8): 2581 - 2589. [Abstract] [Full Text] [PDF]